
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: 1 Department of Internal Medicine (Cancer Research), West German Cancer Center, University Hospital of Essen Medical School, Essen, Germany; 2 Division of Immunology and Infection, University of Birmingham; and 3 The Binding Site Ltd., Birmingham, United Kingdom
Requests for reprints: Mohammad R. Nowrousian, Department of Internal Medicine (Cancer Research), West German Cancer Center, University Hospital of Essen Medical School, Hufelandstrasse 55, 45122 Essen, Germany. Phone: 49-201-723-3127; Fax: 49-201-723-5984; E-mail: nowrousian{at}uni-essen.de.
Purpose: Retrospective studies have shown that immunoassays measuring free light chains (FLC) in serum are useful for diagnosis and monitoring of multiple myeloma. This study prospectively evaluates the use of FLC assays and, for the first time, investigates the relationship between serum FLC concentrations and the presence and detectability of Bence Jones (BJ) proteins in the urine.
Patients and Methods: Three hundred seventy-eight paired samples of serum and urine were tested from 82 patients during the course of their disease. The sensitivities of serum FLC analysis and urine immunofixation electrophoresis (IFE) in detecting monoclonal FLC were compared. Serum FLC concentrations required for producing BJ proteins detected by IFE were determined.
Results: Abnormal FLC were present in 54% of serum samples compared with 25% by urine tests. In abnormal serum samples for
or
, the sensitivity of IFE to detect the respective BJ proteins in urine were 51% and 35% and the median serum FLC concentrations required to produce detectable BJ proteins were 113 and 278 mg/L. Renal excretions of monoclonal FLC increased with serum concentrations, but excretions significantly decreased at high serum concentrations combined with renal dysfunction.
Conclusion: Serum FLC assays are significantly more sensitive for detecting monoclonal FLC than urine IFE analysis. They also have the advantage of FLC quantification and are more reliable for monitoring disease course and response to treatment.
This article has been cited by other articles:
![]() |
D. Siegel, E. Bilotti, and K. H. van Hoeven Serum Free Light Chain Analysis for Diagnosis, Monitoring, and Prognosis of Monoclonal Gammopathies Lab Med, June 1, 2009; 40(6): 363 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Palladini, P. Russo, T. Bosoni, L. Verga, G. Sarais, F. Lavatelli, M. Nuvolone, L. Obici, S. Casarini, S. Donadei, et al. Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine Clin. Chem., March 1, 2009; 55(3): 499 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Abadie, K.H. van Hoeven, and J. M. Wells Are Renal Reference Intervals Required When Screening for Plasma Cell Disorders With Serum Free Light Chains and Serum Protein Electrophoresis? Am J Clin Pathol, February 1, 2009; 131(2): 166 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Hutchison, S. Harding, P. Hewins, G. P. Mead, J. Townsend, A. R. Bradwell, and P. Cockwell Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1684 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Piehler, N. Gulbrandsen, P. Kierulf, and P. Urdal Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population Clin. Chem., November 1, 2008; 54(11): 1823 - 1830. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dispenzieri, L. Zhang, J. A. Katzmann, M. Snyder, E. Blood, R. DeGoey, K. Henderson, R. A. Kyle, M. M. Oken, A. R. Bradwell, et al. Appraisal of immunoglobulin free light chain as a marker of response Blood, May 15, 2008; 111(10): 4908 - 4915. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |